HomeCommentary

Commentary

MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
(Jun.28.2016)

The “sakigake” pricing premium introduced in April was hailed by the pharma industry as something that would improve predictability, because it links drug reviews and reimbursement prices by giving a premium to products designated under the sakigake fast-track review pathway ...

(LOG IN FOR FULL STORY)

News Calendar